抗血管生成药物联合标准二线治疗晚期非小细胞肺癌的个体患者数据Meta分析:ANSELMA研究
在免疫联合化疗已成为晚期非小细胞肺癌一线标准选择的背景下,该个体患者数据Meta分析纳入16项随机试验共8629例患者,评估抗血管生成药物联合标准二线治疗的疗效。结果显示联合抗血管生成药物显著延长总生存期(HR=0.93)和无进展生存期(HR=0.80),但绝对获益有限,主要在年轻患者和一线治疗开始后9个月内启动抗血管生成治疗的患者中更明显。
要点
- 抗血管生成药物联合二线治疗显著延长OS(HR=0.93)和PFS(HR=0.80)。
- OS绝对1年获益为+1.8%,PFS绝对1年获益为+3.5%,临床获益有限。
- OS获益在年轻患者和一线治疗开始后9个月内启动抗血管生成治疗者中更明显。
核心结论
- 在晚期非小细胞肺癌二线治疗中,联合抗血管生成药物可显著延长OS和PFS,但临床获益有限,主要见于年轻患者和一线治疗开始后较短时间内的患者。
研究设计与样本
- 个体患者数据Meta分析,纳入2015年前完成入组的抗血管生成药物联合标准二线治疗对比标准二线治疗 alone 的随机试验,共16项试验、8629例患者,其中64%为腺癌。
主要发现
- 抗血管生成药物联合二线治疗对比标准二线治疗 alone:OS的HR=0.93(95%CI 0.89;0.98),p=0.005;PFS的HR=0.80(95%CI 0.77;0.84),p<0.0001。
- 抗血管生成药物的绝对1年OS获益为+1.8%(95%CI -0.4;+4.0),绝对1年PFS获益为+3.5%(95%CI +1.9;+5.1)。
- 一线治疗开始后9个月内启动抗血管生成治疗的患者OS HR=0.88(95%CI 0.82;0.99),晚于9个月启动者HR=0.99(95%CI 0.91;1.08),交互作用p=0.03;PFS结果相似。
- 抗血管生成药物增加高血压风险(p<0.0001),但不增加肺血栓栓塞事件风险(p=0.21)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Now that immunotherapy plus chemotherapy (CT) is one standard option in first-line treatment of advanced non-small cell lung cancer (NSCLC), there exists a medical need to assess the efficacy of second-line treatments (2LT) with antiangiogenics (AA). We performed an individual patient data meta-analysis to validate the efficacy of these combinations as 2LT. METHODS: Randomised trials of AA plus standard 2LT compared to 2LT alone that ended accrual before 2015 were eligible. Fixed-effect models were used to compute pooled hazard ratios (HRs) for overall survival (OS, main end-point), progression-free survival (PFS) and subgroup analyses. RESULTS: Sixteen trials were available (8,629 patients, 64% adenocarcinoma). AA significantly prolonged OS (HR = 0.93 [95% confidence interval {CI}: 0.89; 0.98], p = 0.005) and PFS (0.80 [0.77; 0.84], p < 0.0001) compared with 2LT alone. Absolute 1-year OS and PFS benefit for AA were +1.8% [-0.4; +4.0] and +3.5% [+1.9; +5.1], respectively. The OS benefit of AA was higher in younger patients (HR = 0.87 [95% CI: 0.76; 1.00], 0.89 [0.81; 0.97], 0.94 [0.87; 1.02] and 1,04 [0.93; 1.17] for patients <50, 50-59, 60-69 and ≥ 70 years old, respectively; trend test: p = 0.02) and in patients who started AA within 9 months after starting the first-line therapy (0.88 [0.82; 0.99]) than in patients who started AA later (0.99 [0.91; 1.08]) (interaction: p = 0.03). Results were similar for PFS. AA increased the risk of hypertension (p < 0.0001), but not the risk of pulmonary thromboembolic events (p = 0.21). CONCLUSIONS: In the 2LT of advanced NSCLC, adding AA significantly prolongs OS and PFS, but the benefit is clinically limited, mainly observed in younger patients and after shorter time since the start of first-line therapy.
引用
- Remon J, Lacas B, Herbst R, et al. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. Eur J Cancer. 2022. PMID: 35286903. doi:10.1016/j.ejca.2022.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。